Simulect Related Published Studies
Well-designed clinical trials related to Simulect (Basiliximab)
Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. [2007.03]
Rabbit antithymocyte globulin versus basiliximab in renal transplantation. [2006.11.09]
A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. [2006.07]
A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. [2006.06.15]
Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. [2006.05]
Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. [2006.05]
Basiliximab: a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation. [2006.04]
A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. [2005.09]
Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. [2005.05]
Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. [2005.04]
Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients. [2005.03]
Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. [2005.02.15]
Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. [2005.02]
Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. [2004.11.27]
Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. [2004.08.27]
Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. [2003.05]
Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. [2003.03]
Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. [2003.01.15]
Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine. [2003.01]
Cost evaluation of basiliximab treatment for renal transplant patients in Japan. [2003]
Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. [2003]
The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. [2002.10]
Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. [2002.02]
Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. [2002.01]
Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. [2001.12.27]
A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. [2001.10.15]
Economic analysis of basiliximab in renal transplantation. [2001.06.15]
An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. [2001.05]
A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. [2001.04]
Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. [2001.04]
A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. [2000.10]
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. [1999.11.15]
Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. [1999.04]
Screening for basiliximab exposure-response relationships in renal allotransplantation. [1999.02]
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. [1999.01.27]
Disposition and immunodynamics of basiliximab in liver allograft recipients. [1998.07]
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. [1997.10.25]
Well-designed clinical trials possibly related to Simulect (Basiliximab)
Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. [2008.06]
Long-term Efficacy and Safety of a Calcineurin Inhibitor-free Regimen in Live-Donor Renal Transplant Recipients. [2008.03.12]
Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. [2007.04.15]
One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. [2007.03]
Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. [2006.04]
Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. [2006.03.27]
Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. [2006]
A multicenter, prospective study of C2-monitored cyclosporine microemulsion in a U.S. population of de novo renal transplant recipients. [2005.10.15]
Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. [2005.10]
Costimulation blockade with belatacept in renal transplantation. [2005.08.25]
Neoral versus prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: three-year results of a single-center, open-label, prospective, randomized pilot study. [2005.07]
Problems of cyclosporine absorption profiling using C2-monitoring. [2005.04.20]
Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. [2005.03]
Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. [2005.03]
A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. [2005.03]
Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. [2004.12]
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. [2004.11.15]
Identifying cyclosporine blood levels associated with the prevention of renal transplant rejection: a single-center, randomized prospective study. [2004.11]
De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. [2004.11]
Use of fenoldopam to control renal dysfunction early after liver transplantation. [2004.08]
Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation. [2004.07.27]
Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. [2004.05]
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. [2004.04]
Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. [2004.01]
Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. [2003.12]
Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients. [2003.06]
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. [2002.10.27]
Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. [2002.10]
Other research related to Simulect (Basiliximab)
Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. [2008.10.15]
Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. [2008.10]
A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. [2008.09.16]
Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. [2008.08.08]
The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series. [2008.07]
Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil. [2008.07]
Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. [2008.05]
Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. [2008.04.15]
Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. [2008.04]
Mycophenolate mofetil: ten years' experience of a renal transplant unit. [2008.04]
Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. [2008.03.11]
Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. [2008.03]
Comparison of outcomes with low-dose anti-thymocyte globulin, basiliximab or no induction therapy in pediatric kidney transplant recipients: a retrospective study. [2008.02]
[Basiliximab following penetrating risk-keratoplasty--a prospective randomized pilot study] [2008.01]
Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. [2008.01]
[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] [2008.01]
Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. [2007.12]
Anaphylactic reaction after initial exposure of Basiliximab: case reports. [2007.12]
The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. [2007.09]
Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. [2007.07.15]
Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. [2007.07]
A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy. [2007.07]
Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. [2007.04.15]
Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. [2007.03]
Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. [2007.03]
Basiliximab improves graft survival in renal transplant recipients with delayed graft function. [2007.03]
The role of basiliximab induction therapy in organ transplantation. [2007.01]
Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. [2007]
Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. [2006.12.20]
Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. [2006.12]
Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation. [2006.11]
Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience. [2006.11]
Effect of basiliximab on renal allograft rejection within 1 year after transplantation. [2006.09]
Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. [2006.08]
Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. [2006.06]
Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. [2006.05.15]
|
